- Home
- PRTA
as 07-11-2025 1:37pm EST
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
| Founded: | 2012 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 346.4M | IPO Year: | N/A |
| Target Price: | $27.67 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.32 - $25.42 | Next Earning Date: | 08-07-2025 |
| Revenue: | $137,935,000 | Revenue Growth: | 54.55% |
| Revenue Growth (this year): | -75.06% | Revenue Growth (next year): | 122.02% |
Stock Insider Trading Activity of Prothena Corporation plc (PRTA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | PRTA | 10% Owner | May 2 '25 | Sell | $8.04 | 6,279,684 | $50,839,807.34 | 8,266,342 |
Latest Prothena Corporation plc News
PRTA Breaking Stock News: Dive into PRTA Ticker-Specific Updates for Smart Investing
BioPharma Dive
23 days ago
Prothena to lay off majority of staff; Zealand shares obesity drug data
Business Wire
24 days ago
Prothena Announces Corporate Restructuring
Insider Monkey
a month ago
Roche’s Phase 3 Move Boosts Outlook for Prothena Corporation plc (PRTA)
TipRanks
a month ago
Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus
BioPharma Dive
a month ago
Roche, waving off study failures, commits to Phase 3 trials for Parkinson’s drug
Zacks
a month ago
RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development
MT Newswires
a month ago
Prothena's Partner to Advance Potential Parkinson's Treatment to Phase 3 Development
Business Wire
a month ago
Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
Compare PRTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRTA Prothena Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.